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The value of standard y-globulin with a low titer of antibody to hepatitis B surface antigen
(anti-HB,) vs hepatitis B immune globulin (HBIG) in prevention of icteric hepatitis B in the
military is unclear. Although recent studies have shown a decrease in icteric hepatitis after
administration of both types of y-globulin in populations where acquisition of hepatitis B virus
(HBV) is most likely the result ofnonparenteral transmission, the data pertaining to parenteral
exposure suggest that HBIG delays the incubation period of HBV and decreases the develop-
ment of passive-active immunity. Since no studies have demonstrated efficacy of standard y-
globulin or HBIG in a drug-using population where multiple HBV exposures are likely, the
results observed in most trials are not comparable to hepatitis B associated with drug abuse in
the military. Therefore, before a recommendation for use of routine -y-globulin or HBIG can be
made for drug-related hepatitis in the military, efficacy of standard -y-globulin and/or HBIG
should be demonstrated in this population.
Although there is little doubt concerning the efficacy of y-globulin in decreasing
the incidence of icteric hepatitis A, the usefulness of standard 'y-globulin or hepatitis
B immune globulin (HBIG) containing a high titer of antibody to hepatitis B surface
antigen (anti-HB,) for prophylaxis against hepatitis B virus (HBV) is unclear. Data
from a number of studies concerning the use of standard y-globulin of varying anti-
Hb, titers, HBIG, or nonimmunized controls have recently become available. These
recent 'y-globulin studies were concerned with the prevention of acquisition of HBV
infection by parenteral or nonparenteral means in populations that have an increased
risk of hepatitis B such as institutionalized children, dialysis patients, and medical
personnel.
Since type B post-transfusion hepatitis is now readily controlled by elimination of
HBSAG+ blood units, the administration of y-globulin is probably not needed for pre-
vention of type B post-blood-transfusion hepatitis. The detection of HB,Ag in body
secretions or excretions would indicate that in contrast to post-transfusion hepatitis,
the dose of HBV transmitted by exposure to this material by parenteral or
nonparenteral routes is low (6, 13). This observation as well as the initial results of
Krugman et al. with HBIG (in institutionalized children (8)) would suggest that
passive immunity might alter disease and/or infection in other high risk populations.
There have been a number of studies of y-globulin administration in a variety of
different populations from which the following conclusions may be drawn (Table 1):
Three different trials (7, 9, 12) all suggest that there is little difference in the efficacy
of standard vs HBIG when given as a prophylactic measure prior to probable
nonparenteral exposure to HBV.
(i) Standard y-globulin which contains a lower titer of anti-HB. has allowed
development of passive-active immunity which most likely leaves the recipient with
long-term immunity. In the study of Szmuness (12) in which a group not receiving
any y-globulin was included, persons given standard y-globulin had a rate of HBV in-
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TABLE I
Clinical Trialsof-y-Globulin in Prevention ofHepatitis B Preexposure Prophylaxis
Icterus or
Reference, Number serological HB,Ag Anti-HBs
population Anti-HBs of HBV anti sero
studied --Globulin titer subjects infection genemia conversion
Iwarson etal.' Standard 1:100 58 2 2 2
Medical personnel HBIG 1:355,000 60 1 2 0
None - 125 9 unknown unknown
Szmuness etal.a Standard 1:16 37 - 2 18
Institutionalized HBIG 1:262,144 44 - 1 8
children None - 52 - 13 20








Prince et al. Standard 1:50 9
Dialysis staff intermediate 1:5,000 296b 8
hyperimmune 1:500,000 4
aMultiple immunizations.
bDialysis staffonly(randomized among threegroups).
fection similar to that of the control group, but the standard "y-globulin did decrease
theincidenceoficteric hepatitis B.
(ii) Prince (9) found no difference in the efficacy of standard vs intermediate-titer
anti-HB, globulin vs HBIG in preventing HBV infection in the medical staff of
dialysis units. However, a statistically significant reduction in the rate of HBV hepa-
titis was noted among dialysis patients who were recipients of HBIG, although no
significant difference was found between the intermediate and standard 'y-globulin
groups.
(iii) A third series of studies deals with administration ofglobulin after accidental
parenteral exposure to HBV-containing blood. Grady et al. (5) and Seeff et al. (11)
have demonstrated a significant decrease in icteric hepatitis B over a 6-month period
in recipients of HBIG as compared to recipients of standard globulin (Table 2). In at
least one trial (5) the effect was nullified by thelack ofdevelopment ofpassive-active
immunity in the HBIG-treated group. The impression gained from this study as well
as that ofRedeker et al. (10) is that hyperimmune -y-globulin decreases the incidence
oficteric hepatitis B but that this effect isonly temporary. Furthermore, HBIG often
suppresses passive-active immunity and may simply increase the incubation period
of hepatitis B. Certainly the results of these studies appear to be somewhat para-
doxical in that the level of anti-HB5 in some cases (9, 12) for presumed low dose
nonparenteral HBV exposure appears to be as efficacious as hyperimmune -y-glob-
ulin. Only Szmuness (12) and Iwarson (7) could show a beneficial effect of
,y-globulin over placebo, since appropriate untreated controls were included.
However, because of the marginal level of anti-HB% in the majority of standard -
globulin preparations used in these studies and the lack ofplacebo (5, 9, 11) controls,
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TABLE 2
Clinical Trials of-y-Globulin in Prevention ofHepatitis B Postexposure Prophylaxis
Icterus or Anti-HBs
Reference, serologic HB.Ag sero
population Anti-HBs Number HBV anti conversion
studied y-Globulin titer subjects infection genemia (%)
Krugman et al. Standard 1:16 5 3
Institutionalized HBIG 1:250,000 10 4
children None - 11 11
Redeker et al. Standard 0 33 9
Spousesofacute HBIG 1:200,000 25 1
HBV cases 1:500,000
Grady etal. Standard 1:50 251 17 90a
Medical personnel intermediate 1:500 208 11 30-40
HBIG 1:500,000 253 5 30-40
Seeffet al. Standard < 1:8 129 8 32
Medical personnel HBIG 1:100,000 134 4 <10
"Approximation data derived from personal communication with Dr. Grady.
bStatistically significant difference at 6 months, but six more cases beyond 6 months in HBIG group
developed nullifying statistical significance.
the efficacy of -y-globulin, particularly in relation to prophylaxis against post-HBV
exposure, remains undetermined.
As a result ofthese recent studies, several recommendations concerning the useof
-y-globulin have been formulated. In an editorial comment Alter et al. (2) suggest
that HBIG or standard y-globulin (containing a low anti-HB, titer) be given (see Ta-
ble 3) until such time as a preparation of high-titered anti-HB, is commercially
available. Because of the noncomparability of military populations with those on
which these recommendations were based, the control of HBV infection by HBIG in
the military cannot be assumed from these studies. From the military viewpoint, the
data derived from such trials and the recommendations issued must be examined in
light of several unique epidemiological aspects not encountered in the present clinical
trials.
Over the last 10 years, a new social phenomenon, illicit drug use, has resulted in
significant increases in HBV infection rates in the military. Epidemics ofhepatitis B
mainly due to HBV/ayw subtype, directly related to illicit drug use, have been ob-
served as bases in the United States (1), as well as in Viet Nam and Germany (3) (Ta-
TABLE 3
Indications for useofHyperimmune Hepatitis B Globulin or Standard Globulin'
Indications
1. Acute "intense" exposure to HBV
a. Parenteral inoculation with HB.Ag in blood or secretions
b. Intimate contact with patients who have acute HBsAg positivehepatitis
2. Repeated HBV exposure (dialysis wards, endemic areas)
a. Standard y-globulin may be more efficacious ifpassive-active immunity is increased
Contraindications
1. Individuals positive for anti-HBs (relative)
2. Post-transfusion hepatitis; few cases exist at present with sensitive RIA techniques that
eliminate HBSAG+ blood units
aEditorial (Alter et al. (2)).
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TABLE 4
Recent Epidemics ofHepatitis B in the Military
Clinical
Location Year attack rate
a
Fort Bragg, North Carolina 1970 20/1000
Fort Hood, Texas 1972 19/1000
Fort Riley, Kansas 1973 10/1000
Germany (USAEUR) 1973 26/1000
Camp Zama, Japan 1974 123/1000
Viet Nam 1972 9.9/1000
Korea 1971 9.2/1000
aApproximation.
ble 4). Attack rates for clinical hepatitis B in some specific units in U.S. Army Divi-
sions in Germany have exceeded 100-200/1000/yr, with an overall attack rate of
26/1000. The economic impact, when one considers length ofhospitalization, conva-
lescent leave following hospitalization, and the effect of loss of manpower to the
military unit, is significant (Table 5). The average length of hospitalization at Fort
Hood was 22 days for the acute hepatitis B patient, followed by 30-60 days ofconva-
lescent leave. In addition, approximately 9% ofthe patients with acutehepatitis have
been readmitted for recurrence of hepatitis associated with abnormal liver function
tests. The cost of HBV disease in Germany alone to the taxpayer is conservatively
estimated to be more than $20,000,000/yr.
Unlike many other infectious diseases, HBV infection, because ofits prolonged in-
cubation period, causes the epidemics to be prolonged over many months to years.
Because oflong foreign tours ofduty, isolation, frustration, inability to communicate
with local populations, and boredom, many low-ranking soldiers turn to occasional
drug use as a means of escape. The recycling of troops with and without previous
HBV experience (as measured by anti-HB.) in and out of such areas leads to a situa-
tion where herd immunity, even among those most likely to use drugs, is rarely
achieved as long as susceptibles are continually admitted to the endemic area.
Several studies (1)' have documented that soldiers with an overseas tour have a prev-
alence of anti-HBs of 25% as compared to 10% in soldiers of the same age with no
foreign experience. In addition, persistence of HB.Ag in a limited study at Fort
Hood, Texas, revealed that 5% of patients with acute HBsAG+ hepatitis failed to
clear their antigenemia 4 months after their initial illness. Thus, a higher prevalence
TABLE 5
Economic Impact ofHepatitis B Infection in Troops at Fort Hood, Texasa
Average length ofhospitalization 20 Days (30-60)
Convalescent leave 30 Days
Assuming an attack rateof 10/100 men among
40,000 troops at Fort Hood 400Cases/year
Work days lost by acutehepatitis B at Fort Hood 20,000 Days
Dollar estimateofloss to U.S. Army in
Germany/year (LaVoie, 1974) $20,000,000
Based on 3,975 hospitalized casesofHepatitis in 1973.
'Dr. Conrad, personal communication (Chief ofClinical Research Walter Reed Army Institute of Re-
search, Wash., D.C.).
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of antigenemia in populations to which anti-HB,-negative susceptibles are
continuously added leads to sustained outbreaks of hepatitis B, particularly when
illicit drug use is in vogue.
Throughout all the recent military hepatitis B epidemics, it appears that, at least
initially, illicit drug use is the major reason for increasing hepatitis rates. Although
difficult to prove, it is likely that nonparenteral HBV transmission due to close
contact also increases in this setting. Such social phenomena as smoking pot and
sharing wine bottles, an almost universal habit among young soldiers, may be a major
source ofnonparenteral transmission of HBV in the military. Certainly, iflow-titered
y-globulin in the military were shown to prevent icteric type B hepatitis and lead to
enhancement of passive-active immunity, repeated exposure to HBV, which
probably occurs in a drug user, would most likely cause a boost in the individual's
anti-HB,.
No trial of -y-globulin or hyperimmune y-globulin to date has been concerned with
a drug-using population, and therefore the data derived from the clinical trials can
only titillate those who would attempt to prevent hepatitis B in the military.
Nevertheless, it is important to recognize that an appropriate trial could be un-
dertaken which might answer the question of y-globulin prophylaxis in the military.
Of necessity, at present certain prerequisites would have to be included: (i) The trial
would have to take place in Germany, where overall attack rates for HBV infection
have declined from 26/1000 in 1973 to 12-15/1000 in 1975. Specific battalion-sized
units with higher attack rates could, however, be selected. (ii) Followup observation
of randomized groups would require at least 1 year from the initial immunization and
take an additional 6 months for analysis of data. (iii) Because of the possibility of
multiple HBV exposures, repeated passive immunizations would have to be given
consideration in the experimental design. This factor would expand the size of the
test population considerably. (iv) Perhaps, under the present ethical conditions, will-
ingness of soldiers, commanders, and particularly drug users to volunteer for such
studies must be clearly recognized as the single most important factor in limiting any
trial in the military, let alone one that is linked to the politically volatile issue ofhepa-
titis and drug abuse.
Thus, in the modern Army such studies of y-globulin and/or vaccine may be
extremely difficult to bring to fruition. Given the above factors, the trial would have
to include a placebo control as well as a standard y-globulin group. The major reason
for this control is apparent from the recent studies in which low-titered 'y-globulin ap-
peared to be as efficacious as hyperimmune preparations in some studies (9, 12),
whereas HBIG prevented passive-active immunity (5). If it is assumed that the data
derived from the two recent needle-stick studies of Grady (5) and Seeff (11)
represent a one-time parenteral drug-related HBV exposure, there is a suggestion
that y-globulin may be of benefit in eradicating hepatitis B disease in the occasional
drug user. It is the low-ranking enlisted man (1) who occasionally uses drugs
parenterally who is most likely to develop acutehepatitis B.
The overall objective of such a trial would be to ascertain the efficacy of-y-globulin
for drug-associated hepatitis B disease and/or infection in the military. The goal
would not be to immunize all troops in the military repeatedly, but, by working in
conjunction with local preventive medicine personnel, to identify high risk military
units with evolving hepatitis B problems. Such units would then be required to submit
to the administration of y-globulin with the aim of preventing disease but perhaps
permitting infection and the resulting synthesis of antibody in all drug abusers. Pro-
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vided these conditions were met, standard -y-globulin or HBIG would serve as an im-
mediate preventive measure until a safe vaccine is available.
Only one recent major study of y-globulin in military troops has been conducted.
The work of Ginsberg et al. (4) showed a decrease in endemic hepatitis B in troops
receiving y-globulin in Korea. The anti-HBs titer of this preparation was 1:4 by
passive hemagglutination, or 1:1024 by radioimmune assay. The hepatitis B cases in
this study were identified early in the evolution of radioimmune assay tests for
HB.Ag, before problems of HB.Ag specificity were recognized. Further, the investi-
gators used extremely sensitive and possibly less specific criteria for stating a test to
be positive (i.e., 3 SD above the negative control mean, as opposed to criteria
evaluated by Abbott Labs and the FDA of 2.1 x negative mean (SD range 5-13)).
Second, the troop population studied was not known to have an illicit drug-use
problem, which suggests that the recognized hepatitis B cases most likely acquired
their HBV by the nonparenteral route. Thus, this study, although potentially offering
a solution to nonparenteral type B exposure in the military, again does not address
the problem of prophylaxis against the repeated low dose parenteral exposure
experienced by illicit drug users.
In conclusion, it should be noted that, even with all the currently available data,
the relevance ofthis information concerning the efficacy ofstandard vs hyperimmune
-y-globulin to the HBV experience in the military today is unknown. No substantial
data exist to provide immediate solutions or recommendations without further inves-
tigations within the military. Thus, it may be appropriate to test the efficacy of -
globulin ofvarying anti-HB, titers as against placebo and to use varying frequencies
ofadministration, as a means ofcontrolling HBV infection in high risk military units.
'y-Globulin obviously is the only temporary measure available until vaccine develop-
ment is completed. However, the problem at present is whether to initiate oy-globulin
trials based on available data or to await the development of a safe HBV vaccine
which is probably 2-5 years in the future. Because of the confusion created by the
recent -y-globulin studies as described, a trial in the military of y-globulin would be
more complex than a two-group trial of HBV vaccine vs placebo. In the long run the
vaccine, ifeffective, will be more economical, easier to administer, and more likely to
produce long-lasting immunity than a y-globulin program. The military may be the
only large population left where efficacy can be defined, but, because of recent stress
on informed consent of volunteers, such testing may not be feasible. Thus, the deci-
sion that must be made is whether to initiate 7y-globulin trials now as a means of
developing a rational policy in view ofthe nature of the recent hepatitis B experience
in the military or whether to await a safe immunogenic vaccine. Either event will cer-
tainly be a test of the ability ofmodern medicine to relate to the modern military in a
setting staged by politicians and lawyers.
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